title: Assessing human papillomavirus vaccine efficacy and safety.
abstract: Clinical trials have documented the safety, efficacy, and immunogenicity of the quadrivalent and bivalent human papillomavirus (HPV) L1 virus-like particle vaccines. These vaccines have demonstrated greater than 90% efficacy in preventing HPV-related neoplasias of the lower genital tract. The quadrivalent HPV vaccine has been found to be more than 95% efficacious in preventing genital warts. These vaccines have been shown to protect against a wider range of oncogenic HPV types. Nonetheless, women must continue to have routine cervical cytologic screening. This article reviews the clinical trials document the efficacy of the HPV vaccines.
authors.affiliation: 4727 St Antoine, Suite 304, Detroit, MI 48201-1461, USA. SHendrix@dmc.org
authors.forename: Susan L
authors.initials: SL
authors.lastname: Hendrix
mesh_terms: D005260:Female; D052162:Human papillomavirus 16; D052161:Human papillomavirus 18; D006801:Humans; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000009:adverse effects*
chemical_list: D053918:Papillomavirus Vaccines